

CIBA-GEIGY

Chemicals Division

CIBA-GEIGY Corporation
P. O. Box 18300
Greensboro, North Carolina 27419-8300
Telephone 919 632 6000

~~Contains NO CBI~~

8E40-92-12306

88920010516

INIT

October 9, 1992

(A)

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Document Processing Center (TS-790)
Office of Toxic Substances
Environmental Protection Agency
401 M. Street, SW
Washington, DC 20460

Attention: Section 8(e) Coordinator (CAP Agreement)

RE: 8E CAP - 0024

Dear Section 8(e) Coordinator:

Enclosed are triplicate copies of a study CIBA-GEIGY Corporation is submitting pursuant to the TSCA Section 8(e) Compliance Audit Program and CAP Agreement number 8E CAP-0024. The information being submitted is not considered Confidential Business Information. We are submitting the following information, as required by the CAP Agreement:

Company Name: CIBA-GEIGY Corporation
444 Saw Mill River Road
Ardsley, New York 10502-2699

Attention: Mr. Anthony Di Battista
Manager, Regulatory Affairs & Toxic Substances
Compliance
Telephone (914) 479-2776

Tested Chemical: 1H-Imidazole-1-ethanol, 2-heptadecenyl-4,5-dihydro-hydrochloride; also identified as Amine O.

CAS No.: 67785-79-9

Report Title: Evaluation of Dermal Effects (I.B.L. Report No. 11368, dated 12/26/72)

Summary: A group of 200 individuals were exposed to a mixture of test materials under occlusion for two days a week for four weeks. Two weeks later, each contact site was challenged with the composite material for 48 hours after which the sites were graded. Composites which elicited reactions during the test were separated into individual components for re-challenge on reacting individuals. Visible skin changes signifying reactions were observed in 5 of the 200 subjects. On re-challenge, one of

3/6/95

Chemicals Division

the components found responsible was the test material identified as Amine O. This study is submitted based on the demonstrated human sensitization potential and potential exposure that may have occurred in the past. The reported chemical substance is no longer a commercial product.

The skin sensitizing potential of the other test material associated with a positive response in this study, identified as Cibaphasol AS, has been submitted under the TSCA 8(e) CAP in a separate letter.

Category: Unit II.B.2.a

Prior Reporting: Not Applicable

Please call the undersigned at telephone number (919) 632-7237 if you have any questions about this submittal.

Very Truly Yours,



Keith A. Hostetler, Ph.D., DABT
Manager, Hazard Assessment
Chemicals Division

Enclosures

2 copies of this letter
3 copies of the study

cc: A. Di Battista

ID # 00262

Food and Drug Research Laboratories
INCORPORATED



Maurice Avenue at 58th Street
Maspeth, New York 11378
Telephone: (212) 894-0800
Cable: Foodlabs, New York

General Medicine

Industrial Biology Division
151 E. 10th Avenue, P.O. Box 424
Conshohocken, Pa. 19428
Telephone: (215) 825-0617

JAN 12 1973

Subject: Evaluation of Dermal Effects

December 26, 1972

Company: CIBA-GEIGY Corporation
Ardsley, New York 10502

Test

Materials: CIBA-GEIGY Name and Identification I. B. L. No.

✓ Cibaphasol AS	11365
Neovadine AN	11366
Tinegal MG	11367
Amine O	11368

Assay: Repeated Insult Patch Test

Study Material
Authorized: 13 April 1972 Received: 1 May 1972

Purpose: To determine if the test material is capable of irritating the skin of humans under controlled test conditions; and, if so, to classify the test material as a primary irritant, fatiguing agent, and/or sensitizer on the basis of the visible clinical responses.

Panel Nos.: 251/72, 252/72, 258/72, 259/72

Procedure: A group of 200 individuals who qualified were selected from a local population. All of these individuals volunteered to participate in this evaluation. The criteria for qualifying were:

1. General well-being.
2. Absence of any skin diseases which might be confused with skin reactions from the test material.
3. Willingness to cooperate.
4. Dependability and intelligence in following directions.
5. Reading, understanding, and signing an informed-consent contract. (In the case of minors, parental consent was obtained.)



Subject: Evaluation of Dermal Effects
Company: CIBA-GEIGY Corporation

December 26, 1972

Procedure:
(Cont'd)

The test materials were applied under occlusion for a series of effective contact periods of two days' duration, i. e., Monday to Wednesday and Wednesday to Friday of each week for four weeks. On Mondays, the test materials were applied. On Wednesdays, the patches were removed, the contact sites examined, and the test materials re-applied for another forty-eight-hour period. On Fridays, the covers were removed and the contact sites were again examined and graded. The contact sites were then rested until the following Monday.

A mixture of the group of four materials was applied to a single predesignated contact site which was reserved for this specific group throughout the test. On each application day, 4% aqueous solutions were freshly made. Fifty ml of the solutions of each of the four test materials comprising each group were then mixed together and one ml was pipetted off to saturate a lintine disc, 1.25 inch in diameter. One such disc was placed intimately in contact with the contact site on each participant and covered with a water impermeable sheet of plastic (1.5 inch by 1.5 inch). The plastic was then affixed to the skin with Blendern tape applied in such a manner as to seal the edges and maintain the integrity of the micro-climate under the patch.

On the second Monday following the removal of the last series of applications, each contact site was challenged with its corresponding composite of test materials. The covers were removed on Wednesday, thereby effecting a challenge contact period of forty-eight hours' duration. The contact sites were examined for visible changes which, if present, were graded and recorded. Sites were re-examined twenty-four and forty-eight hours later for delayed reactions.

Composites which elicited reactions during the test were separated into individual components for re-challenge on reacting individuals. Results of these re-challenge applications are appended.

At all reading periods, it was found useful to wash the sites in order to remove the dyestuffs obscuring the underlying skin. Mild, gentle sponging with warm water was found to be satisfactory.



Subject : Evaluation of Dermal Effects
Company: CIBA-GEIGY Corporation

December 26, 1972

Results: Visible skin changes signifying reaction to injury were observed in 5 of the 200 subjects during the series of application or following the challenge application. On re-challenge, the components found to be responsible were Cibaphasol AS and Amine O.

Conclusions: Despite the reactions elicited by the composite and/or the components contained therein, because of the unusual conditions of the test, it is the opinion of the investigator that the results must be interpreted as indicative of having potential rather than mandatory irritating capabilities.

INDUSTRIAL BIOLOGY DIVISION

MORRIS V. SHELANSKI, M.D., C.M.
Director



Subject: Evaluation of Dermal Effects
 Company: CIBA-GEIGY Corporation
 Material: Composite: Cibaphasol AS, Neovadine AN,
 Tinegal MG, Amine O

December 26, 1972

I. B. L. Nos. 11365 - 11368

SUMMARY OF REACTION GRADES*

Number of subjects negative 195
 Number of subjects showing reactions 5

Number of Application	Number of Reactions in Grades Indicated					NP
	0	1+	2+	3+	4+	
1	199	0	0	1	0	0
2	196	0	3	0	0	1
3	196	0	2	1	0	1
4	196	0	2	1	0	1
5	195	0	0	0	0	5
6	195	0	0	0	0	5
7	195	0	0	0	0	5
8	195	0	0	0	0	5
9	195	0	0	0	0	5
10	195	0	0	0	0	5
11	195	0	0	0	0	5
12	195	0	0	0	0	5
13	195	0	0	0	0	5
14	195	0	0	0	0	5
15	195	0	0	0	0	5
Challenge	195	0	0	0	0	5

*Scoring Criteria:

0 = No reactions.

1+ = Slight erythema.

2+ = Marked erythema.

3+ = Marked erythema, edema, with or without a few vesicles.

4+ = Marked erythema, edema, with vesicles and oozing.

NP = No patch.




Subject: Evaluation of Dermal Effects
 Company: CIBA-GEIGY Corporation
 Material: Composite: Cibaphasol AS, Neovadine AN,
 Tinegal MG, Amine O

December 26, 1972
 I. B. L. Nos. 11365 - 11368

INDIVIDUAL REACTIONS

Subject Number	<u>Exposure Number</u>															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	C
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2	0	2+	<u>3+</u>	NP												
3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Underlined = Change of site.
 NP = No patch.



Subject: Evaluation of Dermal Effects
 Company: CIBA-GEIGY Corporation
 Material: Composite: Cibaphasol AS, Neovadine AN,
 Tinegal MG, Amine O

December 26, 1972
 I. B. L. Nos. 11365 - 11368

INDIVIDUAL REACTIONS

Subject Number	<u>Exposure Number</u>															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	C
26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
27	3+	NP	NP	2+	NP											
28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
36	0	0	0	2+	NP											
37	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0*	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Underlined = Change of site.

NP = No patch.



Subject: Evaluation of Dermal Effects
 Company: CIBA-GEIGY Corporation
 Material: Composite: Cibaphasol AS, Neovadine AN,
 Tinegal MG, Amine O

December 26, 1972
 I. B. L. Nos. 11365 - 11368

INDIVIDUAL REACTIONS

Subject Number	<u>Exposure Number</u>															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	C
51	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
57	0	2+	<u>2+</u>	NP												
58	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
61	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
62	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
63	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
64	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
65	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
66	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
67	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
68	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
69	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
70	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
71	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
72	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
74	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
75	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Underlined = Change of site.

NP = No patch.



Subject: Evaluation of Dermal Effects
 Company: CIBA-GEIGY Corporation
 Material: Composite: CIBAphasol AS, Neovadine AN,
 Tinegal MG, Amine O

December 26, 1972
 I. B. L. Nos. 11365 - 113

INDIVIDUAL REACTIONS

Subject Number	<u>Exposure Number</u>															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	C
101	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
102	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
103	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
104	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
105	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
106	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
107	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
108	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
109	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
110	0	2+	<u>2+</u>	3+	NP											
111	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
112	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
113	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
114	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
115	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
116	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
117	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
118	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
119	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
120	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
121	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
122	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
123	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
124	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
125	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

NP = No patch.
 Underlined = Change of site.



Subject: Evaluation of Dermal Effects
Company: CIBA-GEIGY Corporation

December 26, 1972

REACTIONS TO INDIVIDUAL COMPONENTS OF THE
COMPOSITE MATERIAL

<u>Subject Number</u>	<u>Cibaphasol AS</u> <u>I. B. L. No. 11365</u>	<u>Neovadine AN</u> <u>I. B. L. No. 11366</u>	<u>Tinegal MG</u> <u>I. B. L. No. 11367</u>	<u>Amine O</u> <u>I. B. L. No. 11368</u>
2	1+	0	0	0
27	3+	0	0	0
36	2+	0	0	2+
57	0	0	0	0
110	0	0	0	0



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

Keith A. Hostetler, Ph.D, DABT
Manager, Hazard Assessment
Chemicals Division
CIBA-GEIGY Corporation
P.O. Box 18300
Greensboro, North Carolina 27419-8300

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

APR 24 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

Terry R. O'Bryan
Terry R. O'Bryan
Risk Analysis Branch

Enclosure

12306A



Recycled/Recyclable
Printed with Soy/Canola Ink on paper that
contains at least 50% recycled fiber

Triage of 8(e) Submissions

Date sent to triage: APR 20 1995

NON-CAP

CAP

Submission number: 12306A

TSCA Inventory:

Y N D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX SBTOX SEN w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX CTOX ~~ERI~~ RTOX GTOX
STOX/ONCO CTOX/ONCO IMMUNO CYTO NEUR

Other (FATE, EXPO, MET, etc.): _____

Notes:

THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY

For Contractor Use Only	
entire document: 1 <u>1</u> 2 pages <u>1, 2</u>	pages <u>1, 2, TAB</u>
Notes:	
Contractor reviewer: <u>POZ</u>	Date: <u>4/3/95</u>

CECATS/TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: Submission # 8EHQ-1192-12306 SEQ. A

TYPE: INT SUPP FLWP

SUBMITTER NAME: Ciba-Geigy Corporation

INFORMATION REQUESTED: FLWP DATE:
 0501 NO INFO REQUESTED
 0502 INFO REQUESTED (TECH)
 0503 INFO REQUESTED (VOL ACTIONS)
 0504 INFO REQUESTED (REPORTING RATIONALE)
 DISPOSITION:
 0639 REFER TO CHEMICAL SCREENING
 0678 CAP NOTICE

VOLUNTARY ACTIONS:
 0401 NO ACTION REPORTED
 0402 STUDIES PLANNED/IN PROGRESS
 0403 NOTIFICATION OF WORKERS/OTHERS
 0404 LABEL/MSDS CHANGES
 0405 PROCESS/HANDLING CHANGES
 0406 APP/USE DISCONTINUED
 0407 PRODUCTION DISCONTINUED
 0408 CONFIDENTIAL

SUB. DATE: 10/09/92 OTS DATE: 11/02/92 CSRAD DATE: 03/06/95

CHEMICAL NAME: Amine O
~~Cibapressol AS~~

CAS# 67785-79-9

INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C
0201 ONCO (HUMAN)	01 02 04	0216 EPICLIN	01 02 04	0241 IMMUNO (ANIMAL)	01 02 04
0202 ONCO (ANIMAL)	01 02 04	0217 HUMAN EXPOS (PROD CONTAM)	01 02 04	0242 IMMUNO (HUMAN)	01 02 04
0203 CELL TRANS (IN VITRO)	01 02 04	0218 HUMAN EXPOS (ACCIDENTAL)	01 02 04	0243 CHEM/PHYS PROP	01 02 04
0204 MUTA (IN VITRO)	01 02 04	0219 HUMAN EXPOS (MONITORING)	01 02 04	0244 CLASTO (IN VITRO)	01 02 04
0205 MUTA (IN VIVO)	01 02 04	0220 ECO/AQUA TOX	01 02 04	0245 CLASTO (ANIMAL)	01 02 04
0206 REPRO/ITERATO (HUMAN)	01 02 04	0221 ENV. OCCC/REL/FATE	01 02 04	0246 CLASTO (HUMAN)	01 02 04
0207 REPRO/TERATO (ANIMAL)	01 02 04	0222 EMER INCI OF ENV CONTAM	01 02 04	0247 DNA DAM/REPAIR	01 02 04
0208 NEURO (HUMAN)	01 02 04	0223 RESPONSE REQUEST DELAY	01 02 04	0248 PROD/USE/PROC	01 02 04
0209 NEURO (ANIMAL)	01 02 04	<input checked="" type="checkbox"/> 0224 PROD/COMP/CHEM ID	01 02 04	0251 MSDS	01 02 04
0210 ACUTE TOX. (HUMAN)	01 02 04	0225 REPORTING RATIONALE	01 02 04	0299 OTHER	01 02 04
0211 CHR. TOX. (HUMAN)	01 02 04	0226 CONFIDENTIAL	01 02 04		
0212 ACUTE TOX. (ANIMAL)	01 02 04	<input checked="" type="checkbox"/> 0227 ALLERG (HUMAN)	01 02 04		
0213 SUB ACUTE TOX (ANIMAL)	01 02 04	0228 ALLERG (ANIMAL)	01 02 04		
0214 SUB CHRONIC TOX (ANIMAL)	01 02 04	0239 METAB/PHARMACO (ANIMAL)	01 02 04		
0215 CHRONIC TOX (ANIMAL)	01 02 04	0240 METAB/PHARMACO (HUMAN)	01 02 04		

TRIAGE DATA NON-CBI INVENTORY
 YES
 CAS SR NO
 IN P.A.M.I.

ONGOING REVIEW
 YES (DROP/REFER)
 NO (CONTINUE)
 REFER

SPECIES
 Hmn

TOXICOLOGICAL CONCERN:
 LOW
 MED
 HIGH

USE: PRODUCTION:

COMMENTS

Tox Concern

ID

12306A

SEN
EPI

L(EPI)
H(SEN)

COMMENT

SEN: DERMAL SENSITIZATION IN HUMANS IS OF HIGH CONCERN BASED ON SLIGHT TO MARKED ERYTHEMA (5/200) AT CHALLENGE (1 ML) FOLLOWING OCCLUDED EXPOSURE TO 1.0 ML TWICE/WEEK FOR 4 WEEKS AND A REST PERIOD OF 2 WEEKS.

EPI: THE CHEMICAL WAS TESTED FOR POTENTIAL SKIN SENSITIZATION AND 5 OF 200 SUBJECTS REACTED POSITIVELY. THE CHEMICAL WAS WITHDRAWN FROM COMMERCE.